LONDON – Shield Therapeutics Ltd. signed an exclusive agreement with the UK Medical Research Council (MRC) for PT20, a treatment for hyperphosphatemia caused by kidney disease, and raised €10.5 million (US$13.9 million) for the onward development of the compound, which is ready for Phase II.